Home
About
Overview
Sharing Data
ORCID
Help
History (1)
Phase I clinical and pharmacology study of 502U83 given as a 24-h continuous intravenous infusion.
See All Pages
Find People
Find Everything
Login
to edit your profile (add a photo, awards, links to other websites, etc.)
Edit My Profile
My Person List (
0
)
Return to Top
Phase I clinical and pharmacology study of 502U83 given as a 24-h continuous intravenous infusion.
Phase I clinical and pharmacology study of 502U83 given as a 24-h continuous intravenous infusion. Cancer Chemother Pharmacol. 1993; 31(4):283-8.
View in:
PubMed
subject areas
Adult
Aged
Anthracenes
Antineoplastic Agents
Chromatography, High Pressure Liquid
Clinical Trials, Phase I as Topic
Dose-Response Relationship, Drug
Electrocardiography
Female
Humans
Infusions, Intravenous
Male
Middle Aged
Neoplasms
Respiratory Insufficiency
authors with profiles
Richard Schilsky
Mark J. Ratain